Summary
Regeneron Pharmaceuticals, Inc. reported solid financial performance for the fiscal year ending December 31, 2025, with revenues reaching $14.34 billion and net income at $4.50 billion. The company's strategic focus on scientific innovation and integrated development, manufacturing, and commercialization capabilities continues to drive growth. Key products like Dupixent and EYLEA HD demonstrated strong performance, contributing significantly to the company's top-line results, despite increased competition and the ongoing transition from EYLEA to EYLEA HD. The company also highlighted its robust pipeline with numerous product candidates in various stages of clinical development across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron continues to invest heavily in research and development to fuel future growth. However, investors should be aware of potential headwinds. The company is heavily reliant on its flagship products, EYLEA and Dupixent, and faces significant competition, including from biosimilars for EYLEA. Regulatory and manufacturing challenges were noted, particularly concerning a third-party manufacturer (Catalent) that led to delays in FDA approvals for EYLEA HD's pre-filled syringe and Ordspono. The company is actively managing these issues by onboarding new manufacturers and addressing regulatory feedback. The evolving healthcare landscape, including pricing pressures and potential regulatory changes, also presents risks that investors should monitor.
Financial Highlights
48 data points| Revenue | $14.34B |
| R&D Expenses | $5.85B |
| SG&A Expenses | $2.70B |
| Operating Expenses | $10.77B |
| Operating Income | $3.58B |
| Net Income | $4.50B |
| EPS (Basic) | $43.07 |
| EPS (Diluted) | $41.48 |
| Shares Outstanding (Basic) | 104.60M |
| Shares Outstanding (Diluted) | 108.60M |
Key Highlights
- 1Regeneron reported revenues of $14.34 billion and net income of $4.50 billion for the fiscal year ending December 31, 2025, showing growth from the previous year.
- 2Dupixent continues to be a major growth driver, with Sanofi collaboration revenue (primarily from Dupixent) increasing by over 29% to $5.88 billion.
- 3EYLEA HD and EYLEA combined U.S. net product sales were $4.38 billion, a decrease from 2024, impacted by competitive pressures and the transition to EYLEA HD.
- 4The company experienced delays in the approval of EYLEA HD's pre-filled syringe and Ordspono due to issues identified during a third-party manufacturer's FDA inspection, which the company is actively addressing.
- 5Regeneron's R&D expenses increased by approximately 14% to $5.85 billion, reflecting continued investment in its extensive pipeline of product candidates.
- 6The company maintained a strong balance sheet with $3.12 billion in cash and cash equivalents and $15.40 billion in marketable securities as of December 31, 2025.
- 7Regeneron initiated a quarterly cash dividend program in 2025, signaling a commitment to returning capital to shareholders.